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IMPLEMENTATION AND OPERATIONAL RESEARCH: CLINICAL SCIENCE
What Happens After a Negative Test for Tuberculosis?
Evaluating Adherence to TB Diagnostic Algorithms
in South African Primary Health Clinics
K. M. McCarthy, MD,*† A. D. Grant, PhD,†‡ V. Chihota, PhD,*† S. Ginindza, MSc,*
L. Mvusi, MD,§ G. J. Churchyard, PhD,*†‡ and K.L. Fielding, PhD‡
Introduction and Background: Diagnostic tests for tuberculo-
sis (TB) using sputum have suboptimal sensitivity among
HIV-positive persons. We assessed health care worker adherence
to TB diagnostic algorithms after negative sputum test results.
Methods: The XTEND (Xpert for TB—Evaluating a New Diag-
nostic) trial compared outcomes among people tested for TB in
primary care clinics using Xpert MTB/RIF vs. smear microscopy as
the initial test. We analyzed data from XTEND participants who were
HIV positive or HIV status unknown, whose initial sputum Xpert
MTB/RIF or microscopy result was negative. If chest radiography,
sputum culture, or hospital referral took place, the algorithm for TB
diagnosis was considered followed. Analysis of intervention (Xpert
MTB/RIF) effect on algorithm adherence used methods for cluster-
randomized trials with small number of clusters.
Results: Among 4037 XTEND participants with initial negative test
results, 2155 (53%) reported being or testing HIV positive and 540
(14%) had unknown HIV status. Among 2155 HIV-positive partic-
ipants [684 (32%) male, mean age 37 years (range, 18–79 years)],
there was evidence of algorithm adherence among 515 (24%).
Adherence was less likely among persons tested initially with Xpert
MTB/RIF vs. smear [14% (142/1031) vs. 32% (364/1122), adjusted
risk ratio 0.34 (95% CI: 0.17 to 0.65)] and for participants with
unknown vs. positive HIV status [59/540 (11%) vs. 507/2155 (24%)].
Conclusions: We observed poorer adherence to TB diagnostic
algorithms among HIV-positive persons tested initially with Xpert
MTB/RIF vs. microscopy. Poor adherence to TB diagnostic
algorithms and incomplete coverage of HIV testing represents
a missed opportunity to diagnose TB and HIV, and may contribute
to TB mortality.
Key Words: Tuberculosis, TB/HIV integration, TB diagnosis, Xpert
MTB/RIF, mortality, XTEND
(J Acquir Immune Deﬁc Syndr 2016;71:e119–e126)
INTRODUCTION
The South African tuberculosis (TB) epidemic is one
of the largest in the world, with an estimated incidence of
860 (776–980) cases per 100,000 general population1 in
2013. TB is the leading cause of death among HIV-positive
South Africans.2–4 In this context, prompt diagnosis and
early initiation of TB treatment may save lives. The
diagnosis of TB has been hampered by the poor diagnostic
sensitivity of smear microscopy, especially among HIV-
positive people.5 On the basis of improved sensitivity
compared with smear microscopy,6 the GeneXpert platform
for the diagnosis of TB (Xpert MTB/RIF) was endorsed by
the World Health Organization (WHO) as the initial test for
TB diagnosis among HIV-positive people being investi-
gated for TB,7 as a conditional recommendation, and
subject to resource availability.
The South African National Health Laboratory Service
(NHLS), which provides TB sputum testing for more than
4000 primary health clinics (PHC), rolled out Xpert MTB/RIF,
replacing smear microscopy, as the initial test for TB between
2011 and 2013. The Xpert MTB/RIF roll-out was accompanied
by a new diagnostic algorithm for TB diagnosis (Fig. 1A).8 As
Xpert MTB/RIF is less sensitive than culture, it will miss cases
of TB where the bacterial burden in sputum is lower than the
threshold of detection of c.50–150 colony-forming units (cfu)/
mL.9 The new algorithm therefore advises further investiga-
tions for HIV-positive people whose initial sputum Xpert
MTB/RIF result is negative.10 The algorithm requires sub-
mission of a second sputum specimen for TB culture (followed
by line probe assay or drug susceptibility testing), chest
radiograph (CXR), and a trial of broad-spectrum antibiotics.
These additional tests are appropriate among persons living
with HIV who present with pulmonary symptoms, as the
bacterial burden of TB in sputum is more likely to be low.11
Furthermore, persons living with HIV are more likely to have
TB, and it is appropriate to investigate more intensively.12
In an evaluation of Xpert MTB/RIF vs. smear micros-
copy for the diagnosis of TB (the XTEND trial, described
below),13 we demonstrated no reduction in mortality among
persons tested initially with Xpert MTB/RIF.13 In this
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FIGURE 1. A, The algorithm for the diagnosis of tuberculosis used by health care workers in facilities where GeneXpert testing is
available (used throughout the roll-out for Xpert MTB/RIF, from 2011 to 2014, but only published in the “South African National
Guidelines for TB diagnosis and management” in 2014). B, The algorithm for the diagnosis of tuberculosis used by health care workers
in facilities where GeneXpert testing is not available (South African National Guidelines for TB diagnosis and management, 2009).
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secondary analysis of XTEND trial data, we assessed
adherence to the TB diagnostic algorithm among HIV-
positive adults and adults with unknown HIV status who
had negative sputum tests for TB (either smear microscopy or
XPERT MTB/RIF). In addition, we compared adherence to
the algorithm by study arm and identiﬁed patient factors that
were associated with having had further investigations.
METHODS
XTEND Trial—Study Design and Procedures
The XTEND (Xpert for TB—Evaluating a New Diag-
nostic) study was a pragmatic, 2-arm, parallel, cluster-
randomized trial evaluating the effectiveness of Xpert MTB/
RIF implementation in South Africa (Current Controlled
Trials: ISRCTN68905568; South African Clinical Trial
Register: DOH-27-1011-3849).14 During Xpert MTB/RIF
roll-out, 20 laboratories in 4 provinces were identiﬁed to
receive Xpert MTB/RIF machines. Forty PHCs served by but
not colocated with these participating laboratories were
identiﬁed for participation in XTEND. Twenty clusters, each
comprising a NHLS laboratory and 2 PHC facilities, were
allocated using stratiﬁed randomization to Xpert MTB/RIF
(immediate implementation) or microscopy (with Xpert
MTB/RIF implementation deferred) arms.13 Participant
enrollment in the Xpert arm was initiated a median of 3.6
(range, 1–7.4) months after the laboratory started routine use
of Xpert MTB/RIF.13 XTEND study staff enrolled a system-
atic sample drawn from persons undergoing sputum testing at
the request of clinic staff and obtained baseline data including
personal identiﬁers, locator information, demographic and
clinical data relevant to TB and mortality risk. Study staff
(who were masked to the results of sputum investigations and
who also had no inﬂuence on clinical investigations done by
clinic staff) kept contact with participants until 6 months after
enrollment, when study staff reviewed patient’s clinic records
for sputum results, evidence of additional investigations
including sputum culture, chest radiograph, or broad-
spectrum antibiotic prescription, TB treatment start dates, or
documented referral to hospital. For logistical reasons, we did
not review participants’ hospital records for evidence of
relevant investigations. Six months after enrollment, study
staff interviewed participants telephonically, or by home visit,
to ascertain whether they had started TB treatment, had an
HIV test or CD4 count, started antiretroviral therapy, or had
been admitted to hospital. After completion of follow-up,
investigators also obtained XTEND participant sputum results
from the NHLS laboratory information system. XTEND
study methods are described more completely elsewhere.13
Study Setting—Baseline Characteristics of
Participating Clinics and Implementation of
Xpert MTB/RIF in XTEND Clinics
Among 40 PHCs identiﬁed for participation in
XTEND, 17 facilities (43%) were situated in a predominantly
rural area (mean population density within 2.5 km2 radius
,150 persons/km2). During the 3 months before start of
enrollment into XTEND, participating clinics recorded
a median of 4787 [interquartile range (IQR), 2353–6345]
patient visits and conducted a median of 116 (IQR, 59–195)
TB tests per month. The median number of patients per clinic
who received TB treatment each month was 33 (IQR, 20–66).
Nine clinics (23%) had radiography facilities on site, while
those facilities without referred patients to the nearest hospital
for chest radiography, a mean of 7 km away. During the
national roll-out of Xpert MTB/RIF, TB control program staff
and TB nurses for PHC facilities in the districts that were
earmarked for implementation received training on the use of
Xpert MTB/RIF and the algorithm for TB diagnosis (Fig.
1A). Training was conducted by University Research Corpo-
ration of South Africa (for clinical staff) and the NHLS (for
laboratory staff). TB control program staff arranged on-site
training for nurses from the larger facilities, whereas work-
shops attended by clinic TB nurses were held at central
locations, and nurses were asked to return to their facility and
train the clinical staff who had not attended the session. The
algorithm in Figure 1A was made available as a wall chart
and distributed to implementing facilities. Laboratories not
earmarked to receive Xpert MTB/RIF, including those
randomized to delayed Xpert MTB/RIF, continued to use
smear microscopy as the initial test for TB, and the clinics
continued to use the algorithm advised by the 2009 South
African TB guidelines (Fig. 1B).15 At all participating clinics,
clinic staff identiﬁed persons who required investigation for
TB according to local practice, and XTEND study staff did
not change this. In both arms, when initial sputum test results
were negative for TB, further investigations (sputum myco-
bacterial culture, chest radiography, and therapeutic trial of
antibiotics) or referral to hospital was made at the discretion
of the PHC health care worker. In clinics using Xpert MTB/
RIF, staff had recently been trained in the use of the new
algorithm for TB diagnosis, as described above, whereas in
clinics using smear microscopy, no additional training was
given as part of XTEND trial procedures.
Criteria for Inclusion in the Secondary
Data Analysis
To evaluate adherence to the algorithm for the diagno-
sis of TB among persons with known HIV infection,
a secondary analysis of XTEND data was conducted.
Participants in the main XTEND study who were HIV
positive or HIV status unknown and whose sputum tests at
enrollment were Xpert MTB/RIF or smear microscopy
negative were included in the data set.
Case Definitions
Participants were deﬁned as “index test negative” if, at,
or within 4 days of enrollment, both sputum specimens for
smear microscopy or the one sputum specimen for Xpert
MTB/RIF taken, were negative. Participants were identiﬁed
as being HIV positive if there was evidence in the clinical
record (any of a positive HIV test, prescription of antire-
troviral therapy, or evidence of other HIV care), or partic-
ipants reported being HIV positive or on antiretroviral agents
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at enrollment interview. The TB diagnostic algorithm was
regarded as having been followed if there was evidence in the
clinic records at the enrollment PHC or laboratory record
during the 6-month follow-up period of any of (1) chest
radiograph, (2) sputum for mycobacterial culture, and (3)
referral to hospital for further investigations. Although we
collected data on antibiotic prescription within 2 months of
enrollment, the provision of antibiotics was not included in
the deﬁnition of adherence to algorithm, although it is part of
the algorithm, as record review could not distinguish
“therapeutic trial” of antibiotics from prescription for another
purpose.16 Referral to hospital was regarded as “adhering to
the algorithm” as this is described in the NDoH10 and WHO16
algorithms when persons investigated for TB have respiratory
distress or require investigations for extrapulmonary TB.
Furthermore, referral is a reasonable alternative if further
investigations are not possible at the PHC.
Statistical Analysis
Statistical analysis was conducted using STATA (ver-
sion 12; StataCorp LP, College Station, TX). Analysis of the
intervention (implementation of Xpert MTB/RIF) effect on
algorithm adherence (deﬁned above) was based on methods
appropriate to the trial design with a small number of clusters17
and restricted to HIV-positive patients. Brieﬂy, the analysis
was conducted at the cluster level giving clusters equal weight
and using log transformation of the cluster-level risk of the
outcome. The risk ratio was calculated as the ratio of geometric
means for Xpert MTB/RIF vs. microscopy arms, taking into
account the stratiﬁed randomization. An approximate standard
error of the log (risk ratio) was obtained based on the residual
mean square from a 2-way analysis of variance of the cluster-
level log risk on randomization stratum, study arm, and the
interaction between stratum and study arm.17 This was used to
calculate 95% CI for the risk ratio and associated P value. An
adjusted risk ratio was calculated using a 2-stage approach,
adjusting for baseline imbalance by study arm.17
Analysis of patient factors associated with adherence to
the algorithm for TB diagnosis was performed combining
data across study arm from HIV-positive patients and
using logistic regression with random effects to account for
between-clinic variation. Factors with evidence of an associ-
ation with the outcome (P value ,0.05) in the univariable
analysis were included in the multivariable model and
retained in the model if the P value ,0.05. Adjusted odd
ratios (aORs) and 95% CIs are reported. A priori, sex and age
group were included in the fully adjusted model.
RESULTS
Participant Characteristics
Of the 4656 XTEND participants, 4411 had an index test
result available; of whom, 4037 (92%) had a negative test
result. Among these 4037 participants, 2155 (53%) were HIV
positive, and 540 (13%) had unknown HIV status, and were
included in this analysis. Demographic and medical character-
istics of these 2695 participants stratiﬁed by study arm and
HIV status are shown in Table 1. Participants with HIV
positive or unknown serostatus (n = 2695) had a mean age of
38 years (range, 18–94 years) and 941 (35%) participants were
male. Forty-one percent (1113/2695) had at least 3 TB
symptoms and 2189 (81%) had attended a health care facility
at least once before enrollment to address their TB symptoms.
Ten percent (273/2695) of participants had a body mass index
(BMI) less than 18.5. Of 2155 who were HIV positive at
enrollment, 662 (31%) were on antiretroviral therapy, and of
the 944 with CD4 result available, 31% (292) had a CD4 count
less than 200 cells per cubic millimeter. As in the main
XTEND cohort,13 those in the smear microscopy arm tended to
have more TB symptoms, a lower BMI, and lower Karnofsky
score than those in the Xpert MTB/RIF arm.
Investigations for Tuberculosis
Among 2155 HIV-positive participants, during the 6
months after a negative index test result, evidence of further
investigations or interventions (such as referral to hospital) was
found in clinic records for 24% (507) of participants (Table 2).
Evidence for sputum culture was found for 427 (20%)
participants, and chest radiography was documented in 4%
(89/2153) participants’ ﬁles, performed a median of 14 days
after enrollment (IQR, 2–31 days). Eight participants (7 and one
in the Xpert MTB/RIF and microscopy arms, respectively) died
within 2 weeks of enrollment, of whom only one participant
had evidence of further investigations. Among 540 participants
with unknown HIV status, no evidence of further investigations
was found in clinic records for 89% (481), 10% (54) had
a sputum culture, 2% (9) had chest radiography, and 2% (11)
were referred to hospital. No participants with unknown HIV
status died within 2 weeks of enrollment.
Among HIV-positive participants, the algorithm was
followed in 14% (142/1031) of participants in the Xpert MTB/
RIF arm, compared with 32% (365/1124) of persons in the
smear microscopy arm, yielding an unadjusted risk ratio of
0.32 (95% CI: 0.17 to 0.62), which was similar after
adjustment for gender, age, and exposures of TB symptoms
and BMI (adjusted risk ratio, 0.34; 95% CI: 0.17 to 0.65).
Combining data across study arms, patient-level factors
associated with a higher odds of adherence to the algorithm
among persons with known HIV status were male gender; 2 or
more previous clinic visits at the time of enrollment versus none;
and more severe illness at enrollment, as manifested by having
more TB symptoms, a lower BMI, lower Karnofsky score, and
CD4 count below 350 cells per cubic millimeter (Table 3). In
a multivariable model, having 3 or more TB symptoms (aOR,
1.59; 95% CI: 1.14 to 2.23) and 2 or more previous visits to
clinic (aOR, 1.42; 95% CI: 0.97 to 2.10) remained associated
with increased odds of having had further investigations. Being
female (aOR, 0.66; 95% CI: 0.51 to 0.88) was associated with
decreased odds of having had further investigations. Participants
with unknown HIV status were less likely to be investigated
further [59/540 (11%) vs. 507/2155 (24%)] compared with
participants with known HIV-positive status.
Among participating clinics, and for those who
were sputum test negative, there was large between-clinic
variation in ascertainment of participant HIV status and
adherence to algorithms. The percentage of participants at
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each clinic in whom HIV status was not ascertained ranged
from 1% to 41%. Evidence of partial adherence to the
algorithm, including chest radiography, TB culture, or referral
for further investigations ranged from 0% to 86% at partici-
pating clinics. Among participants with negative index sputum
tests and known HIV-positive status, 7 clinics performed
sputum culture in over 50% of persons, while 21 clinics
requested sputum culture on less than 5% of persons. Chest
radiography was performed only occasionally at any clinic,
with 14 clinics having no evidence of chest radiography among
HIV-positive persons with negative index sputum tests.
DISCUSSION
In this evaluation of routine primary health care practice
among persons being investigated for TB in the context of
a pragmatic trial, we observed poor adherence to TB diagnostic
algorithms when initial sputum tests were negative, and fewer
investigations (sputum TB cultures or chest radiography)
among persons with negative Xpert MTB/RIF compared with
persons with negative smears. Coverage of HIV testing was
also suboptimal. Failure to adhere to this algorithm represents
a missed opportunity for TB diagnosis and HIV testing, and
may have contributed to the high mortality rate in this cohort.13
Although it is well established that adherence to the 2007
(pre-Xpert) WHO algorithm for the diagnosis of smear-negative
TB (ie, the addition of sputum culture, chest radiography, and
a trial of antibiotics) increases algorithm sensitivity, shortens
time to TB treatment initiation, and reduces mortality,18–22
there are no studies explicitly evaluating the effectiveness of
the current South African algorithm (incorporating Xpert) for
TB diagnosis. However, 2 South African studies illustrate the
potential for additional investigations, speciﬁcally chest
radiography, to facilitate TB diagnosis. In a prospective
TABLE 1. Characteristics of XTEND Participants With Negative Result on the Index Sputum Test Who Were HIV Positive, or Who
had Unknown HIV Status, by Study Arm and HIV Status (n = 2695)
Smear Microscopy Arm: n (Column %) GeneXpert Arm: n (Column %)
HIV Status HIV Status
Positive
(n = 1124)
Status Unknown
(n = 239)
Positive
(n = 1031)
Status Unknown
(n = 301)
Gender
Male 384 (34) 108 (45) 300 (29) 149 (50)
Age category, yrs
,30 268 (24) 58 (24) 296 (29) 86 (29)
30–39 443 (39) 37 (15) 388 (38) 65 (22)
$40 413 (37) 144 (60) 347 (34) 150 (50)
Number of TB symptoms†
0–1 273 (24) 64 (27) 352 (34) 94 (31)
2 290 (26) 73 (31) 320 (31) 116 (39)
3 or 4 561 (50) 102 (43) 359 (35) 91 (30)
Number of previous visits to
primary health care facility
0 168 (15) 49 (21) 216 (21) 73 (24)
1 520 (46) 111 (46) 459 (45) 181 (60)
$2 436 (39) 79 (33) 356 (35) 47 (16)
ART status
on ART 343 (30) n/a 319 (30) n/a
CD4* cell count category
(in cells/mm3)
,200 292 (31) n/a 276 (32) n/a
200–249 305 (32) n/a 237 (28) n/a
$350 347 (37) n/a 355 (41) n/a
BMI category, kg/m2
,18.5 137 (12) 27 (11) 78 (8) 31 (10)
18.5–25 527 (47) 104 (44) 478 (46) 112 (37)
.25 460 (41) 108 (45) 475 (46) 158 (52)
Karnofsky category
100 150 (13) 97 (41) 204 (20) 151 (50)
90 469 (41) 121 (51) 393 (38) 105 (35)
10–80 505 (45) 21 (9) 434 (42) 44 (15)
*The CD4 cell count could not be ascertained from record review for 342 participants.
†Of cough, fever, night sweats, weight loss.
n/a, not applicable.
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evaluation of persons undergoing a single Xpert MTB/RIF
test for TB diagnosis in a single PHC, of 116 persons started
on TB treatment after initial Xpert MTB/RIF, 66 (57%) were
Xpert MTB/RIF negative, of whom 44 had chest radiography
or clinical evidence suggestive of TB.23 Subsequently 22
(50%) of these 44 persons had a positive sputum culture.23 In
the TB-NEAT study among participants tested initially with
Xpert MTB/RIF, only half of those starting TB treatment did
so on the basis of a positive Xpert MTB/RIF.24 In the XTEND
study population, in which 89% of persons with negative
initial sputum results had no further investigations for TB, the
omission of additional investigations may have led to
poor outcomes.
The XTEND study identiﬁed that persons with unknown
HIV status had a greater mortality risk when compared to
persons with HIV-positive status and those on antiretroviral
therapy.13 Our analysis reveals that persons with unknown HIV
status are also less likely to receive further investigations for
TB when initial sputum tests are negative. We and others
demonstrate that persons living in areas with high HIV
seroprevalence whom health care workers identify as requiring
TB investigations have an HIV prevalence more than 50%25,26
and should therefore receive priority for HIV testing, staging,
and rapid initiation of antiretroviral therapy. Failure to ascertain
HIV status when initial sputum tests are negative for TB may
lead to inappropriate underinvestigation for TB.
There are few reported studies that assess adherence
to TB diagnostic guidelines in Africa. Among patients
diagnosed in hospital, Loveday (South Africa)27 and
Tafuma (Botswana)28 reported poor adherence to TB
diagnostic algorithms, with a dependence on chest radiog-
raphy and little use of sputum microscopy or culture. In an
urban and rural setting in Uganda, Alamo et al18 reported
poor adherence under operational conditions to the WHO
2007 algorithm for smear-negative TB. In the study of
Alamo, reasons for nonadherence included failure by
patients to attend for follow-up and operational constraints,
such as absence of a doctor to interpret the chest
radiography, or supply chain problems with radiographic
reagents. In Ethiopia,29 physicians cited the absence of
appropriate diagnostic modalities, ambiguity in TB guide-
lines, lack of faith in laboratory results, including smear
microscopy, as reasons for failure to adhere to TB
diagnostic guidelines. Patient difﬁculty in making multiple
visits to health facilities was cited as a reason why doctors
included radiography along with smear microscopy at
patient’s initial visit.29 In Ethiopia, poor documentation
and lack of transparency regarding which investigations had
been done hampered adherence to guidelines when patients
were required to visit multiple service providers.29
Review of diagnostic algorithms may identify simpler
or more effective strategies to diagnose TB. For example, in
certain provinces in South Africa, where XTEND was not
conducted but Xpert MTB/RIF is implemented, 2 sputum
samples are sent simultaneously to the laboratory, which
retains the second specimen for further testing if necessary.
Efforts to strengthen adherence to TB diagnostic pathways
could include mentoring and on-site supervision.
In general, inadequate adherence to guidelines across
the spectrum of clinical disciplines, providers, and country
income strata is a recognized problem that contributes to poor
health outcomes.30–32 Reasons for inadequate adherence
include guideline complexity, omission of the target user
group in drawing up guidelines, weaker implementation
strategies, lack of awareness of or familiarity with guidelines
among the users, and a negative attitude or limited support
from peers or superiors.31 A study in Uganda32 reported
duplicated content, conﬂicting guidelines, and difﬁculties in
guideline dissemination. Importantly, a mismatch between
guidelines and conditions on the ground made implementa-
tion difﬁcult.32 Even when guidelines were available, a “cul-
ture of not reading guidelines” was cited by managers as one
of the difﬁculties faced by implementers. Poor supervision by
superiors, who face logistical obstacles and who are burdened
TABLE 2. Further Investigations and Interventions at Enrollment Clinic Among Participants in the XTEND Study During the
6-Month Follow-up Period After Enrollment, Stratified by Study Arm and HIV Status (n = 2695)
Adherence to
Algorithm
Number (Column %) of Participants With Investigation Done*
Entire Cohort
(n = 2695)
Smear Microscopy
Arm (n = 1363)
Xpert MTB/RIF
Arm
HIV Positive
(n = 2155)
[n (%)]
HIV Status
Unknown
(n = 540)
[n (%)]
HIV
Positive
(n = 1124)
[n (%)]
HIV Status
Unknown
(n = 239)
[n (%)]
HIV
Positive
(n = 1031)
[n (%)]
HIV Status
Unknown
(n = 301)
[n (%)]
No adherence No further investigations
or interventions
1648 (76) 481 (89) 759 (68) 195 (82) 889 (86) 286 (95)
Partial adherence At least one of chest
radiography, sputum
culture, or referral
507 (24) 59 (11) 365 (32) 44 (18) 142 (14) 15 (5)
Sputum culture 428 (20) 54 (10) 316 (28) 42 (18) 112 (11) 1 (0)
Chest radiography† 89 (4) 9 (2) 57 (5) 5 (2) 32 (3) 4 (1)
Referred to hospital 80 (4) 11 (2) 39 (3) 1 (0) 41 (4) 10 (3)
*Among HIV-positive participants, 8 participants died within 2 weeks of enrollment, only one of whom had chest radiography. No participants among those with unknown HIV
status died within 2 weeks of enrollment.
†Chest radiography was performed a median of 14 days after enrollment (interquartile range, 2–31 days).
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with administrative responsibilities, contributes to difﬁculties
in guideline implementation. In our analysis, reasons for poor
adherence are difﬁcult to ascertain as the parent study was not
designed to address this question. However, the high burden
of persons requiring additional TB investigations and oper-
ational constraints when chest radiography is not available at
site with logistical issues regarding patient transport may be
among the reasons. Furthermore in our study, the relatively
poorer adherence in the arm using Xpert MTB/RIF, despite
recent training in the newer algorithm, may indicate that
nurses place more conﬁdence in a negative Xpert MTB/RIF
result than is warranted. The fact that, across both arms,
nurses tended to conduct further investigations on participants
who were more ill (as evidenced by increasing number of TB
symptoms, BMI, and Karnofsky score) is reassuring.
The strengths of our analysis include the pragmatic
design of the parent study, allowing examination of current
practice, large sample size including multiple clinics across
rural and urban sites, multiple information sources to
determine algorithm adherence (patient interview, case note
abstraction and NHLS laboratory information system), and
the opportunity to compare adherence to the algorithm during
the roll-out of Xpert MTB/RIF. To our knowledge, it is
also the ﬁrst such evaluation of adherence to the new South
African TB diagnostic algorithm in an operational setting.
Limitations of the pragmatic study design are the absence of
a gold standard for TB diagnosis, thus we are unable to
quantify the effect of poor algorithm adherence in terms of
numbers of cases of TB missed. Although we collected data
on provision of antibiotics, data were limited and did not
permit us to distinguish between antibiotics given as part of
the TB diagnostic algorithm from those given for other
purposes such as co-trimoxazole prophylaxis or to treat
bacterial infections. In addition, we did not cross-check
algorithm adherence with participant hospital records, nor
were we able to examine health care worker rationale behind
TABLE 3. Patient factors at Enrollment Associated With Health Care Workers’ adherence to the Algorithm for the Diagnosis of
Tuberculosis Amongst HIV-positive Persons With Negative Initial Tests for Tuberculosis (n = 2155)
Partial Adherence to the
Algorithm (n/N, Row %) OR (95% CI)*
P value†
(p-Trend) aOR (95% CI)
P value†
(p-Trend)
Gender
Male 201/684 (29) Ref ,0.001 Ref 0.003
Female 306/1471 (20) 0.64 (0.49–0.83) 0.66 (0.51–0.88)
Age category, yrs
,30 119/564 (21) Ref 0.41 Ref 0.31
30–39 205/831 (25) 1.2 (0.87–1.64) 1.11 (0.81–1.53)
$40 183/760 (24) 1.02 (0.74–1.42) 0.88 (0.63–1.24)
Number of TB Symptoms
0–1 121/625 (19) Ref 0.002 (Pt , 0.001) Ref 0.02
2 144/610 (23) 1.34 (0.96–1.89) 1.24 (0.87–1.75)
3 or 4 242/920 (26) 1.78 (1.29–2.47) 1.59 (1.14–2.23)
Number of previous visits to
health care facility
0 92/384 (24) Ref ,0.001 Ref 0.002
1 181/979 (19) 0.84 (0.58–1.23) 0.83 (0.57–1.22)
$2 234/792 (29) 1.50 (1.02–2.20) 1.42 (0.97–2.10)
ART status
On ART 173/662 (26) Ref 0.86
Not on ART 334/1493 (22) 0.98 (0.75–1.27)
CD4, cells/mm3
,200 143/569 (25) Ref 0.49
200–249 141/541 (26) 0.99 (0.71–1.39)
$350 162/703 (23) 0.84 (0.61–1.16)
BMI category, kg/m2
,18.5 58/215 (27) 1.36 (0.89–2.10) 0.008 (Pt = 0.001)
18.5–25 252/1005 (25) Ref
.25 197/935 (21) 0.73 (0.55–0.95)
Karnofsky category
100 74/354 (21) Ref 0.06 (Pt = 0.02)
90 206/862 (24) 1.64 (0.98–2.74)
10–80 227/939 (24) 1.92 (1.12–3.29)
*From logistic regression with random effects to control for between-clinic variation.
†P value from likelihood ratio test.
ART, antiretroviral therapy.
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clinical judgments taken when patients returned for sputum
results. We are also not able to differentiate patient vs. health
system factors contributing to nonadherence.
In this study among a large cohort of persons under-
going TB investigations, drawn from 40 PHCs across 4 South
African provinces, our analysis provides evidence that under
routine clinic conditions at least 60% of HIV-positive persons
with negative index sputum test results have no evidence of
further investigation for TB. Persons tested initially with
Xpert MTB/RIF were less likely to receive additional
investigations. Furthermore, we observed that persons with
negative initial TB tests and unknown HIV status were even
less likely to receive additional investigations. In our South
African context, national mortality risk among persons
diagnosed with TB exceeds 8%, and postmortem studies
indicated high rates of undiagnosed TB among deaths in
community.33 We recommend targeted efforts to improve the
uptake of HIV testing among all persons undergoing inves-
tigations for TB. TB diagnostic pathways need to be reviewed
and strengthened to ensure that a negative sputum test result
is not the end of the diagnostic road, particularly for those at
highest risk of poor outcomes.
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